Adjusted EBIT improved by 33% year-over-year, with strong U.S. growth and cost-saving measures. A rights issue of SEK 29.4m is planned to fund FDA process completion and U.S. expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.